Clicky

SELVITA S.A. SER.B ZY-80(787)

Description: Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, autoimmune/immunology, neurology, respiratory, and other. In addition, the company provides drug development services, including formulation development; CMC analytical support; stability and shelf-life determination; clinical supply/GMP manufacturing; small molecules bioanalysis; drug substance and product; and biologics and biosimilars bioanalysis services. Further, it offers research and development services in the areas of agrochemistry analytical support, and flavor and fragrance chemistry. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.


Keywords: Biopharmaceutical Artificial Intelligence Infectious Diseases Pharmacology Drug Discovery Drug Development Biosimilar Assay Biochemistry Drug Design Drug Discovery Services Drug Development Services Bioanalysis

Home Page: selvita.com

Hexagon
Kraków, 30-394
Poland
Phone: 48 123 00 50 01


Officers

Name Title
Mr. Boguslaw Stanislaw Sieczkowski M.B.A. Chairman of Management Board & CEO
Dr. Milosz Kazimierz Gruca Ph.D. Chief Commercial Officer, Executive VP & Vice President of Management Board
Mr. Dariusz Tomasz Kurdas CFO & Member of the Management Board
Dr. Miroslawa Monika Zydron Ph.D. COO & Member of the Management Board
Mr. Dawid Patryk Radziszewski General Counsel & Member of the Management Board
Dr. Adrijana Vinter Global Head of Drug Discovery & Member of the Management Board

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 17.7681
Price-to-Book MRQ: 3.0341
Price-to-Sales TTM: 0.693
IPO Date:
Fiscal Year End: December
Full Time Employees: 886
Back to stocks